Raissa Almeida
Researcher at the Federal University of Rio Grande do Norte (UFRN)
Data updated
Papers
Trials
Research Footprint
Raissa Almeida appears in 5 tracked papers (2021–2025), most studied alongside DMT, Psilocybin and Placebo, across Healthy Volunteers, Depressive Disorders and Anxiety Disorders.
Most-cited paper: Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression (27 citations).
Frequent co-authors: Fernanda Palhano-Fontes, Draulio Araújo and Nathalia Galvão-Coelho.
Background & Research
Raissa Almeida appears to be a Brazilian researcher affiliated with the Federal University of Rio Grande do Norte (UFRN) and the DMT clinical research team led by Draulio Araujo and collaborators. She is listed as a coauthor on several psychedelic research papers, including phase I/II studies of inhaled or vaporized N,N-dimethyltryptamine (DMT) and a study on psychedelic drug use and schizotypy in young adults.
Key Impact
Coauthor on multiple DMT clinical studies from the UFRN/Brain Medicine group, contributing to early human evidence on inhaled/vaporized DMT for depression and safety.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Raissa Almeida is associated with.